If you're a member of the press, you can contact us at communications@catalysiscapital.com
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Vascular Flow Technologies Limited on the restructuring of £7,000,000 in outstanding loan notes into Series A Ordinary Preference shares as well as the concurrent closing of a £3,000,000 Series B financing round. The Series B round was led by […]
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series C financing raising £1,500,000. The round was led by Octopus Investments and supported by Smith & Nephew, Kent County Council and several individual angel investors. Michelson Diagnostics (Kent, United Kingdom) develops, manufactures and […]
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series D financing raising £2,500,000. The round was led by Smith & Nephew and Kent County Council and supported by Octopus Investments and several individual angel investors. Michelson Diagnostics (Kent, United Kingdom) develops, manufactures […]
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Michelson Diagnostics, Ltd. in a Series A2 financing raising £1,977,779. The round was led by Octopus Investments and supported by Catapult Venture Managers Ltd, London Business Angels and several individual angel investors. Michelson Diagnostics Ltd. (Orpington, United Kingdom) is […]
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Diagnoplex SA in connection with the signing of a collaborative agreement with Unilabs SA for the European commercialization of Colox®. Financial terms were not disclosed.
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to ERYTECH Pharma SA in securing €5.0 million from Recordati in the form of a convertible note. The transaction was concurrent with ERYTECH Pharma signing a licensing and distribution agreement with Orphan Europe for GRASPA® in Europe. Orphan Europe is […]
CATALYISS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Dipylon Medical AB on the sale of its Eirus Medical business unit assets to MAQUET, part of GETINGE GROUP. Financial terms were not disclosed.
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Molecular Vision Ltd. on the sale of a controlling equity stake to Abingdon Health Ltd. Financial terms were not disclosed.
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Dipylon Medical AB on the sale of its clinical microdialysis assets and wholly-owned subsidiary in the United States to M Dialysis AB. Financial terms were not disclosed.
CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive strategic advisor to CMA Microdialysis AB on the sale of its preclinical microdialysis assets and related intellectual property to Harvard Bioscience, Inc. Financial terms were not disclosed.